Coats Completes Acquisition of OrthoLite, Strengthening Footwear Business
Acquisition aligns with Coats’ Long-Term Growth Strategy in Apparel and Footwear
Coats Group plc, a world-leading Tier 2 supplier of critical components to the apparel and footwear industries, announced today that it has completed its acquisition of OrthoLite, a global market leader in footwear materials and the number one brand in premium insoles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030015142/en/
OrthoLite Vietnam
The acquisition marks a major milestone in the Company’s long-term growth plans and strengthens its existing footwear division through expansion into the attractive, high-growth premium insole segment. Both companies already have a similar customer base, a complementary global footprint and a commitment to industry-leading innovation and sustainability practices.
“OrthoLite is one of the world’s most innovative manufacturers in footwear materials. With our combined capabilities, we’ll now be able to offer our customers more future-focused solutions for more of the shoe – without compromising on the trusted quality both companies stand for,” said David Paja, Group Chief Executive Officer.“We’re delighted to officially welcome Glenn and the OrthoLite team to the Coats family.”
Coats first announced its intention to purchase OrthoLite, and its sustainable materials brand, Cirql, on July 16, 2025, for an initial enterprise value of $770 million. Following previous footwear acquisitions, this is the latest step in the Company’s ambition to shape the future of the global apparel and footwear supply chain through innovation, sustainability, and digital technologies that improve quality, efficiency and performance.
“I’m confident this move will bring even more value and opportunity for our customers and our people, while still delivering the great partnership and collaboration we’ve taken pride in over the years,” said Glenn Barrett, Founder and CEO of OrthoLite. “After 28 years leading the way in premium insoles, I look forward to this next era of growth with Coats.”
To better reflect its increased scale and expanded footwear capabilities, Coats will also move from a three-division organisational structure, previously Apparel, Footwear and Performance Materials, toward a simplified two‑division structure focused on Apparel and Footwear. Existing Performance Materials businesses will be folded into the two new divisions.
The divisions will be led byPasquale Abruzzese, Footwear CEO and Group Chief Operating Officer, and Adrian Elliott, Apparel CEO and Group Chief Commercial Officer. Glenn Barrett will continue to lead the OrthoLite business. External reporting will transition to this structure for the financial year ending December 2026.
About Coats Group plc
Coats is a world-leading Tier 2 manufacturer and trusted partner for the apparel and footwear industries. We deliver essential materials, components, and software solutions that help our customers grow, compete and win.
With over 250 years of industry expertise, we’re shaping the future of the apparel and footwear supply chain through insight-led innovation, impactful sustainability practices, and digital technologies that unlock better product quality, efficiency and performance.
Headquartered in the UK, Coats is a FTSE 250 company and a constituent of the FTSE4Good Index. In 2024, we generated $1.5 billion in revenue and employed 16,000 people worldwide—all united by a spirit of innovation, quality and service. Learn more at www.coats.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030015142/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release
An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 14:00:00 CET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 13:45:00 CET | Press release
Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation. Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecu
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory30.10.2025 13:30:00 CET | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories. Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability, and quality. The designation affirms that Crown Bioscience’s Suzhou laboratory meets all required compliance benchmarks, providing clients with greater confidence in the biomarker data that supports their clinical development and regulatory submissions. ‘’Earning a second CLIA certification within
SLB OneSubsea Secures EPC Contracts from PTTEP for Two Deepwater Projects Offshore Malaysia30.10.2025 13:30:00 CET | Press release
Integrated subsea production systems will help unlock important oil and gas reserves Global energy technology company SLB (NYSE: SLB) announced today the award of two sizeable engineering, procurement, and construction (EPC) contracts by PTT Exploration and Production Public Company Limited (PTTEP) to its OneSubsea™ joint venture. The contracts build on a 20-year collaboration between the two companies and cover the expansion of two fields offshore Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030090404/en/ As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom